These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27979310)

  • 1. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.
    Sahu D; Gupta S; Hau AM; Nakashima K; Leivo MZ; Searles SC; Elson P; Bomalaski JS; Casteel DE; Boss GR; Hansel DE
    Am J Pathol; 2017 Jan; 187(1):200-213. PubMed ID: 27979310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
    Gupta S; Sahu D; Bomalaski JS; Frank I; Boorjian SA; Thapa P; Cheville JC; Hansel DE
    Endocr Pathol; 2018 Sep; 29(3):236-241. PubMed ID: 29453600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
    Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
    Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
    Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
    Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
    Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
    Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
    Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
    Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    Mörén L; Perryman R; Crook T; Langer JK; Oneill K; Syed N; Antti H
    BMC Cancer; 2018 Feb; 18(1):167. PubMed ID: 29422017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
    Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
    Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
    Miraki-Moud F; Ghazaly E; Ariza-McNaughton L; Hodby KA; Clear A; Anjos-Afonso F; Liapis K; Grantham M; Sohrabi F; Cavenagh J; Bomalaski JS; Gribben JG; Szlosarek PW; Bonnet D; Taussig DC
    Blood; 2015 Jun; 125(26):4060-8. PubMed ID: 25896651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
    Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
    Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
    Cheon DJ; Walts AE; Beach JA; Lester J; Bomalaski JS; Walsh CS; Ruprecht Wiedemeyer W; Karlan BY; Orsulic S
    J Pathol Clin Res; 2015 Jan; 1(1):41-53. PubMed ID: 27499892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.